Certara, Inc. (CERT) Stock Analysis
Range Bound setup
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $5.16, but acceptable to hold if already in. Reason: Market cap $0.81B below $1B minimum.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia... Read more
Hold if already holding. Not a fresh buy at $5.16, but acceptable to hold if already in. Reason: Market cap $0.81B below $1B minimum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Market cap $0.81B below $1B minimum. Not in investable universe. Score 4.6/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Certara, Inc.
Latest news
- NEWS Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8 — benzinga May 12, 2026
- NEWS BMO Capital Maintains Market Perform on Certara, Lowers Price Target to $6 — benzinga May 12, 2026
- NEWS Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $6.5 — benzinga May 12, 2026
- NEWS Stephens & Co. Maintains Overweight on Certara, Lowers Price Target to $9 — benzinga May 12, 2026
- NEWS Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $10 — benzinga May 12, 2026
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 6.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.16, but acceptable to hold if already in. Reason: Market cap $0.81B below $1B minimum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Market cap $0.81B below $1B minimum. Not in investable universe. Target $6.51 (+26.2%), stop $4.84 (−6.6%), A.R:R 1.7:1. Score 4.6/10, moderate confidence.
Take-profit target: $6.51 (+25.2% upside). Target $6.51 (+26.2%), stop $4.84 (−6.6%), A.R:R 1.7:1. Stop-loss: $4.84.
Market cap $0.81B below $1B minimum.
Certara, Inc. trades at a P/E of N/A (forward 12.6). TrendMatrix value score: 8.5/10. Verdict: Hold.
20 analysts cover CERT with a consensus score of 3.8/5. Average price target: $7.
What does Certara, Inc. do?Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for...
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.